Financials data is unavailable for this security.
View more
Year on year Novo Nordisk A/S grew revenues 31.26% from 176.95bn to 232.26bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 50.71% net income growth from 55.53bn to 83.68bn.
| Gross margin | 84.60% |
|---|---|
| Net profit margin | 36.03% |
| Operating margin | 44.16% |
| Return on assets | 30.12% |
|---|---|
| Return on equity | 88.07% |
| Return on investment | 63.12% |
More ▼
Cash flow in DKKView more
In 2023, Novo Nordisk A/S increased its cash reserves by 13.74%, or 1.74bn. The company earned 108.91bn from its operations for a Cash Flow Margin of 46.89%. In addition the company used 43.89bn on investing activities and also paid 63.16bn in financing cash flows.
| Cash flow per share | 20.24 |
|---|---|
| Price/Cash flow per share | 32.58 |
| Book value per share | 23.90 |
|---|---|
| Tangible book value per share | 10.35 |
More ▼
Balance sheet in DKKView more
| Current ratio | 0.8231 |
|---|---|
| Quick ratio | 0.6356 |
| Total debt/total equity | 0.2534 |
|---|---|
| Total debt/total capital | 0.2022 |
More ▼
Growth rates in DKK
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 51.61% and 52.38%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 1.68% |
|---|---|
| Div growth rate (5 year) | 18.20% |
| Payout ratio (TTM) | 50.17% |
| EPS growth(5 years) | 18.50 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 53.12 |
More ▼
